171 related articles for article (PubMed ID: 27629950)
1. Comparative Study of Infliximab Therapy and Methotrexate Monotherapy to Improve the Clinical Effect in Rheumatoid Arthritis Patients.
Miwa Y; Isojima S; Saito M; Ikari Y; Kobuna M; Hayashi T; Takahashi R; Kasama T; Hosaka M; Sanada K
Intern Med; 2016; 55(18):2581-5. PubMed ID: 27629950
[TBL] [Abstract][Full Text] [Related]
2. Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis.
van der Kooij SM; le Cessie S; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; van Zeben D; Kerstens PJ; Hazes JM; van Schaardenburg D; Breedveld FC; Dijkmans BA; Allaart CF
Ann Rheum Dis; 2009 Jul; 68(7):1153-8. PubMed ID: 18930988
[TBL] [Abstract][Full Text] [Related]
3. Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial.
Stamm TA; Machold KP; Aletaha D; Alasti F; Lipsky P; Pisetsky D; Landewe R; van der Heijde D; Sepriano A; Aringer M; Boumpas D; Burmester G; Cutolo M; Ebner W; Graninger W; Huizinga T; Schett G; Schulze-Koops H; Tak PP; Martin-Mola E; Breedveld F; Smolen J
Arthritis Res Ther; 2018 Aug; 20(1):174. PubMed ID: 30092827
[TBL] [Abstract][Full Text] [Related]
4. Infliximab, methotrexate and their combination for the treatment of rheumatoid arthritis: a systematic review and meta-analysis.
Costa Jde O; Lemos LL; Machado MA; Almeida AM; Kakehasi AM; Araújo Vde E; Cherchiglia ML; Andrade EI; Acurcio Fde A
Rev Bras Reumatol; 2015; 55(2):146-58. PubMed ID: 25593074
[TBL] [Abstract][Full Text] [Related]
5. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.
Karlsson JA; Neovius M; Nilsson JÅ; Petersson IF; Bratt J; van Vollenhoven RF; Ernestam S; Geborek P
Ann Rheum Dis; 2013 Dec; 72(12):1927-33. PubMed ID: 23196701
[TBL] [Abstract][Full Text] [Related]
6. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.
Maini RN; Breedveld FC; Kalden JR; Smolen JS; Furst D; Weisman MH; St Clair EW; Keenan GF; van der Heijde D; Marsters PA; Lipsky PE;
Arthritis Rheum; 2004 Apr; 50(4):1051-65. PubMed ID: 15077287
[TBL] [Abstract][Full Text] [Related]
7. Infliximab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis -- a randomized trial.
Tam LS; Shang Q; Li EK; Wang S; Li RJ; Lee KL; Leung YY; Ying KY; Yim CW; Kun EW; Leung MH; Li M; Li TK; Zhu TY; Chui RK; Tseung L; Yu SL; Kuan WP; Yu CM
J Rheumatol; 2012 Dec; 39(12):2267-75. PubMed ID: 22984272
[TBL] [Abstract][Full Text] [Related]
8. Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: an open, randomized, controlled trial.
Kurasawa T; Nagasawa H; Kishimoto M; Amano K; Takeuchi T; Kameda H
Mod Rheumatol; 2014 Jul; 24(4):561-6. PubMed ID: 24252035
[TBL] [Abstract][Full Text] [Related]
9. A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment.
Durez P; Nzeusseu Toukap A; Lauwerys BR; Manicourt DH; Verschueren P; Westhovens R; Devogelaer JP; Houssiau FA
Ann Rheum Dis; 2004 Sep; 63(9):1069-74. PubMed ID: 15308515
[TBL] [Abstract][Full Text] [Related]
10. Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis.
Pérez-Guijo VC; Cravo AR; Castro Mdel C; Font P; Muñoz-Gomariz E; Collantes-Estevez E
Joint Bone Spine; 2007 May; 74(3):254-8. PubMed ID: 17387031
[TBL] [Abstract][Full Text] [Related]
11. Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy.
Bergstra SA; Landewé RBM; Huizinga TWJ; Allaart CF
Rheumatology (Oxford); 2017 Oct; 56(10):1721-1728. PubMed ID: 28957556
[TBL] [Abstract][Full Text] [Related]
12. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score.
van der Kooij SM; de Vries-Bouwstra JK; Goekoop-Ruiterman YP; van Zeben D; Kerstens PJ; Gerards AH; van Groenendael JH; Hazes JM; Breedveld FC; Allaart CF; Dijkmans BA
Ann Rheum Dis; 2007 Oct; 66(10):1356-62. PubMed ID: 17293364
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis.
Lie E; van der Heijde D; Uhlig T; Heiberg MS; Koldingsnes W; Rødevand E; Kaufmann C; Mikkelsen K; Kvien TK
Ann Rheum Dis; 2010 Apr; 69(4):671-6. PubMed ID: 19740904
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study.
Strand V; Rentz AM; Cifaldi MA; Chen N; Roy S; Revicki D
J Rheumatol; 2012 Jan; 39(1):63-72. PubMed ID: 22045836
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Long-Term Baricitinib With and Without Methotrexate for the Treatment of Rheumatoid Arthritis: Experience With Baricitinib Monotherapy Continuation or After Switching From Methotrexate Monotherapy or Baricitinib Plus Methotrexate.
Fleischmann R; Takeuchi T; Schiff M; Schlichting D; Xie L; Issa M; Stoykov I; Lisse J; Martinez-Osuna P; Rooney T; Zerbini CAF
Arthritis Care Res (Hoboken); 2020 Aug; 72(8):1112-1121. PubMed ID: 31233281
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA.
Kimel M; Cifaldi M; Chen N; Revicki D
J Rheumatol; 2008 Feb; 35(2):206-15. PubMed ID: 18085743
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of infliximab: A comparison with other biological disease-modifying anti-rheumatic drugs.
Kobayashi D; Ito S; Takai C; Hasegawa E; Nomura Y; Otani H; Abe A; Ishikawa H; Murasawa A; Narita I; Nakazono K
Mod Rheumatol; 2018 Jul; 28(4):599-605. PubMed ID: 28972441
[TBL] [Abstract][Full Text] [Related]
18. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate.
Rigby W; Ferraccioli G; Greenwald M; Zazueta-Montiel B; Fleischmann R; Wassenberg S; Ogale S; Armstrong G; Jahreis A; Burke L; Mela C; Chen A
Arthritis Care Res (Hoboken); 2011 May; 63(5):711-20. PubMed ID: 21557525
[TBL] [Abstract][Full Text] [Related]
19. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients.
Aletaha D; Funovits J; Keystone EC; Smolen JS
Arthritis Rheum; 2007 Oct; 56(10):3226-35. PubMed ID: 17907167
[TBL] [Abstract][Full Text] [Related]
20. Rescue of combination therapy failures using infliximab, while maintaining the combination or monotherapy with methotrexate: results of an open trial.
Ferraccioli GF; Assaloni R; Di Poi E; Gremese E; De Marchi G; Fabris M
Rheumatology (Oxford); 2002 Oct; 41(10):1109-12. PubMed ID: 12364628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
